Fingolimod is a potential novel therapy for multiple sclerosis

Nature Reviews Neurology

Volumn 6, Issue 7, 2010, Pages 373-382

  Aktas, Orhan ^a   Küry, Patrick ^a   Kieseier, Bernd ^a   Hartung, Hans Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; PLACEBO; SPHINGOSINE 1 PHOSPHATE RECEPTOR; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ALLERGIC ENCEPHALOMYELITIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMMON COLD; DISEASE MODEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HEART RATE; HERPES SIMPLEX ENCEPHALITIS; HERPES ZOSTER ENCEPHALITIS; HUMAN; LOW DRUG DOSE; LYMPHOCYTE MIGRATION; MULTIPLE SCLEROSIS; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SINUSITIS; SKIN CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE; MOUSE; PHYSIOLOGY; RAT;

ANIMALS; CELL MOVEMENT; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MICE; MULTIPLE SCLEROSIS; NERVE REGENERATION; PROPYLENE GLYCOLS; RATS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 77954864204     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2010.76     Document Type: Review

References (84)

1. Fujita, T. et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J. Antibiot. (Tokyo) 47, 208-215 (1994).
2. Brinkmann, V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br. J. Pharmacol. 158, 1173-1182 (2009).
3. Schwab, S. R. & Cyster, J. G. Finding a way out: lymphocyte egress from lymphoid organs. Nat. Immunol. 8, 1295-1301 (2007).
4. Foster, C. A. et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J. Pharmacol. Exp. Ther. 323, 469-475 (2007).
5. Miron, V. E., Schubart, A. & Antel, J. P. Central nervous system-directed effects of FTY720 (fingolimod). J. Neurol. Sci. 274, 13-17 (2008).
6. Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402-415 (2010).
7. Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387-401 (2010).
8. Takabe, K., Paugh, S. w., Milstien, S. & Spiegel, S. "Inside-out" signaling of sphingosine- 1-phosphate: therapeutic targets. Pharmacol. Rev. 60, 181-195 (2008).
9. Fukushima, N., Ishii, I., Contos, J. J., Weiner, J. A. & Chun, J. Lysophospholipid receptors. Annu. Rev. Pharmacol. Toxicol. 41, 507-534 (2001).
10. Spiegel, S. & Milstien, S. Sphingosine-1- phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 4, 397-407 (2003).
11. Gardell, S. E., Dubin, A. E. & Chun, J. Emerging medicinal roles for lysophospholipid signaling. Trends Mol. Med. 12, 65-75 (2006).
12. Chun, J. et al. International Union of Pharmacology. XXXIv. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 54, 265-269 (2002).
13. Dev, K. K. et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol. Ther. 117, 77-93 (2008).
14. Budde, K. et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 13, 1073-1083 (2002).
15. Chiba, K. et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 160, 5037-5044 (1998). (Pubitemid 28215340)
16. Henning, G. et al. CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. J. Exp. Med. 194, 1875-1881 (2001).
17. Brinkmann, V. et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277, 21453-21457 (2002).
18. Mandala, S. et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296, 346-349 (2002).
19. Matloubian, M. et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427, 355-360 (2004).
20. Mullershausen, F. et al. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat. Chem. Biol. 5, 428-434 (2009).
21. Rivera, J., Proia, R. L. & Olivera, A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat. Rev. Immunol. 8, 753-763 (2008).
22. Walzer, T. et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat. Immunol. 8, 1337-1344 (2007).
23. Michaud, J., Im, D. S. & Hla, T. Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J. Immunol. 184, 1475-1483 (2010).
24. Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S. & Oursler, M. J. Regulation of bone formation by osteoclasts involves wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl Acad. Sci. USA 105, 20764-20769 (2008).
25. Ishii, M. et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458, 524-528 (2009).
26. Cinamon, G. et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat. Immunol. 5, 713-720 (2004).
27. Cinamon, G., Zachariah, M. A., Lam, O. M., Foss, F. W. Jr & Cyster, J. G. Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat. Immunol. 9, 54-62 (2008).
28. Donovan, E. E., Pelanda, R. & Torres, R. M. S1P3 confers differential S1P-induced migration by autoreactive and non-autoreactive immature B cells and is required for normal B-cell development. Eur. J. Immunol. 40, 688-698 (2010).
29. Goverman, J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 9, 393-407 (2009).
30. Venken, K., Hellings, N., Liblau, R. & Stinissen, P. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol. Med. 16, 58-68 (2010).
31. Gandhi, R., Laroni, A. & Weiner, H. L. Role of the innate immune system in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 221, 7-14 (2009).
32. Lunemann, J. D. & Munz, C. Do natural killer cells accelerate or prevent autoimmunity in multiple sclerosis? Brain 131, 1681-1683 (2008).
33. Frohman, E. M., Racke, M. K. & Raine, C. S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 354, 942-955 (2006).
34. Beer, M. S. et al. EDG receptors as a therapeutic target in the nervous system. Ann. NY Acad. Sci. 905, 118-131 (2000).
35. Teshima, K. et al. FTY720, a novel immunosuppressant, possessing unique mechanisms III. Pharmacological activities in several autoimmune and inflammatory models [abstract 864]. In Abstracts of the 9th International Congress of Immunology. 5126 (1995).
36. Steinman, L. & Zamvil, S. S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 26, 565-571 (2005).
37. Gold, R., Linington, C. & Lassmann, H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129, 1953-1971 (2006).
38. Stromnes, I. M. & Goverman, J. M. Active induction of experimental allergic encephalomyelitis. Nat. Protoc. 1, 1810-1819 (2006).
39. Ben-Nun, A., Wekerle, H. & Cohen, I. R. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 11, 195-199 (1981).
40. Aktas, O., Ullrich, O., Infante-Duarte, C., Nitsch, R. & Zipp, F. Neuronal damage in brain inflammation. Arch. Neurol. 64, 185-189 (2007).
41. Ransohoff, R. M. EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis. Trends Immunol. 27, 167-168 (2006).
42. Bartholomaus, I. et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 462, 94-98 (2009).
43. Greter, M. et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 11, 328-334 (2005).
44. Aktas, O. et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46, 421-432 (2005).
45. Krishnamoorthy, G. et al. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat. Med. 15, 626-632 (2009).
46. Fujino, M. et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 305, 70-77 (2003).
47. Liu, G. et al. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat. Immunol. 10, 769-777 (2009).
48. Webb, M. et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. 153, 108-121 (2004).
49. Kataoka, H. et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol. Immunol. 2, 439-448 (2005).
50. Rausch, M. et al. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultra small superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 20, 16-24 (2004).
51. Balatoni, B. et al. FTY720 sustains and restores neuronal function in the DA rat model of MOGinduced experimental autoimmune encephalomyelitis. Brain Res. Bull. 74, 307-316 (2007).
52. Papadopoulos, D. et al. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J. Neurosci. Res. 88, 346-359 (2009).
53. Foster, C. A. et al. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol. 19, 254-266 (2009).
54. Brinkmann, V., Cyster, J. G. & Hla, T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. 4, 1019-1025 (2004).
55. Lee, J. F. et al. Dual roles of tight junctionassociated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. J. Biol. Chem. 281, 29190-29200 (2006).
56. Miron, V. E. et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann. Neurol. 63, 61-71 (2008).
57. Miron, V. E., Hall, J. A., Kennedy, T. E., Soliven, B. & Antel, J. P. Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am. J. Pathol. 173, 1143-1152 (2008).
58. Coelho, R. P., Payne, S. G., Bittman, R., Spiegel, S. & Sato-Bigbee, C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J. Pharmacol. Exp. Ther. 323, 626-635 (2007).
59. Jung, C. G. et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 55, 1656-1667 (2007).
60. Novgorodov, A. S., El-Alwani, M., Bielawski, J., Obeid, L. M. & Gudz, T. I. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J. 21, 1503-1514 (2007).
61. Miron, V. E. et al. The immunomodulator fingolimod (FTY720) increases myelin production following demyelination of organotypic cerebellar slices [abstract S47.003]. Neurology 72 (Suppl. 3), A421 (2009).
62. Rouach, N. et al. S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ ROCK. Eur. J. Neurosci. 23, 1453-1464 (2006).
63. Osinde, M., Mullershausen, F. & Dev, K. K. Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology 52, 1210-1218 (2007).
64. Sofroniew, M. V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 32, 638-647 (2009).
65. Prozorovski, T. et al. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat. Cell Biol. 10, 385-394 (2008).
66. Kremer, D. et al. p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation. Proc. Natl Acad. Sci. USA 106, 9087-9092 (2009).
67. Mullershausen, F. et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J. Neurochem. 102, 1151-1161 (2007).
68. Pebay, A. et al. Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades. Eur. J. Neurosci. 13, 2067-2076 (2001).
69. Postma, F. R., Jalink, K., Hengeveld, T. & Moolenaar, w. H. Sphingosine-1-phosphate rapidly induces Rho-dependent neurite retraction: action through a specific cell surface receptor. EMBO J. 15, 2388-2392 (1996).
70. Edsall, L. C., Pirianov, G. G. & Spiegel, S. Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation. J. Neurosci. 17, 6952-6960 (1997).
71. Moore, A. N., Kampfl, A. w., Zhao, X., Hayes, R. L. & Dash, P. K. Sphingosine-1- phosphate induces apoptosis of cultured hippocampal neurons that requires protein phosphatases and activator protein-1 complexes. Neuroscience 94, 405-415 (1999).
72. Toman, R. E. et al. Differential transactivation of sphingosine-1- phosphate receptors modulates NGF-induced neurite extension. J. Cell Biol. 166, 381-392 (2004).
73. Harada, J., Foley, M., Moskowitz, M. A. & Waeber, C. Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J. Neurochem. 88, 1026-1039 (2004).
74. Kimura, A. et al. Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 25, 115-124 (2007).
75. Picard-Riera, N. et al. Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice. Proc. Natl Acad. Sci. USA 99, 13211-13216 (2002).
76. Menn, B. et al. Origin of oligodendrocytes in the subventricular zone of the adult brain. J. Neurosci. 26, 7907-7918 (2006).
77. Mizugishi, K. et al. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell Biol. 25, 11113-11121 (2005).
78. Kappos, L. et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355, 1124-1140 (2006).
79. Mehling, M. et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71, 1261-1267 (2008).
80. O'Connor, P. et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72, 73-79 (2009).
81. Hartung, H. P. & Aktas, O. Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope. Ann. Neurol. 66, 429-432 (2009).
82. Saab, G., Almony, A., Blinder, K. J., Schuessler, R. & Brennan, D. C. Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient. Arch. Ophthalmol. 126, 140-141 (2008).
83. Hartung, H. P. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol. 8, 28-31 (2009).
84. Leypoldt, F. et al. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 72, 1022-1024 (2009).